Gilead Sciences, Inc.
GILD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $28,754,000 | $27,116,000 | $27,281,000 | $27,305,000 |
| % Growth | 6% | -0.6% | -0.1% | – |
| Cost of Goods Sold | $6,251,000 | $6,498,000 | $5,657,000 | $6,601,000 |
| Gross Profit | $22,503,000 | $20,618,000 | $21,624,000 | $20,704,000 |
| % Margin | 78.3% | 76% | 79.3% | 75.8% |
| R&D Expenses | $5,907,000 | $5,718,000 | $4,977,000 | $4,601,000 |
| G&A Expenses | $2,638,000 | $2,818,000 | $4,895,000 | $4,511,000 |
| SG&A Expenses | $6,091,000 | $6,090,000 | $5,673,000 | $5,246,000 |
| Sales & Mktg Exp. | $3,453,000 | $3,272,000 | $778,000 | $735,000 |
| Other Operating Expenses | $8,843,000 | $1,205,000 | $3,644,000 | $939,000 |
| Operating Expenses | $20,841,000 | $13,013,000 | $14,294,000 | $10,786,000 |
| Operating Income | $1,662,000 | $7,605,000 | $7,330,000 | $9,918,000 |
| % Margin | 5.8% | 28% | 26.9% | 36.3% |
| Other Income/Exp. Net | -$972,000 | -$746,000 | -$1,516,000 | -$1,640,000 |
| Pre-Tax Income | $690,000 | $6,859,000 | $5,814,000 | $8,278,000 |
| Tax Expense | $211,000 | $1,247,000 | $1,248,000 | $2,077,000 |
| Net Income | $480,000 | $5,665,000 | $4,592,000 | $6,225,000 |
| % Margin | 1.7% | 20.9% | 16.8% | 22.8% |
| EPS | 0.38 | 4.54 | 3.66 | 4.96 |
| % Growth | -91.6% | 24% | -26.2% | – |
| EPS Diluted | 0.38 | 4.5 | 3.64 | 4.93 |
| Weighted Avg Shares Out | 1,247,000 | 1,248,000 | 1,255,000 | 1,256,000 |
| Weighted Avg Shares Out Dil | 1,255,000 | 1,258,000 | 1,262,000 | 1,262,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $281,000 | $376,000 | $106,000 | $0 |
| Interest Expense | $977,000 | $944,000 | $935,000 | $1,001,000 |
| Depreciation & Amortization | $2,767,000 | $2,693,000 | $2,103,000 | $2,050,000 |
| EBITDA | $4,434,000 | $10,496,000 | $8,852,000 | $11,329,000 |
| % Margin | 15.4% | 38.7% | 32.4% | 41.5% |